205 related articles for article (PubMed ID: 27239040)
1. PIAS1 Promotes Lymphomagenesis through MYC Upregulation.
Rabellino A; Melegari M; Tompkins VS; Chen W; Van Ness BG; Teruya-Feldstein J; Conacci-Sorrell M; Janz S; Scaglioni PP
Cell Rep; 2016 Jun; 15(10):2266-2278. PubMed ID: 27239040
[TBL] [Abstract][Full Text] [Related]
2. c-Myc is targeted to the proteasome for degradation in a SUMOylation-dependent manner, regulated by PIAS1, SENP7 and RNF4.
González-Prieto R; Cuijpers SA; Kumar R; Hendriks IA; Vertegaal AC
Cell Cycle; 2015; 14(12):1859-72. PubMed ID: 25895136
[TBL] [Abstract][Full Text] [Related]
3. The transcriptional activity of co-activator AIB1 is regulated by the SUMO E3 ligase PIAS1.
Li S; Yang C; Hong Y; Bi H; Zhao F; Liu Y; Ao X; Pang P; Xing X; Chang AK; Xiao L; Zhang Y; Wu H
Biol Cell; 2012 May; 104(5):287-96. PubMed ID: 22283414
[TBL] [Abstract][Full Text] [Related]
4. The transcriptional repression activity of KyoT2 on the Notch/RBP-J pathway is regulated by PIAS1-catalyzed SUMOylation.
Wang J; Qin H; Liang J; Zhu Y; Liang L; Zheng M; Han H
J Mol Biol; 2007 Jun; 370(1):27-38. PubMed ID: 17509614
[TBL] [Abstract][Full Text] [Related]
5. An oncogenic axis of STAT-mediated BATF3 upregulation causing MYC activity in classical Hodgkin lymphoma and anaplastic large cell lymphoma.
Lollies A; Hartmann S; Schneider M; Bracht T; Weiß AL; Arnolds J; Klein-Hitpass L; Sitek B; Hansmann ML; Küppers R; Weniger MA
Leukemia; 2018 Jan; 32(1):92-101. PubMed ID: 28659618
[TBL] [Abstract][Full Text] [Related]
6. Protein inhibitor of activated STAT1 Ser
Liu SY; Ma YL; Hsu WL; Chiou HY; Lee EHY
Br J Pharmacol; 2019 Jun; 176(11):1793-1810. PubMed ID: 30849179
[TBL] [Abstract][Full Text] [Related]
7. PIAS1 is a GATA4 SUMO ligase that regulates GATA4-dependent intestinal promoters independent of SUMO ligase activity and GATA4 sumoylation.
Belaguli NS; Zhang M; Garcia AH; Berger DH
PLoS One; 2012; 7(4):e35717. PubMed ID: 22539995
[TBL] [Abstract][Full Text] [Related]
8. Proinflammatory stimuli induce IKKalpha-mediated phosphorylation of PIAS1 to restrict inflammation and immunity.
Liu B; Yang Y; Chernishof V; Loo RR; Jang H; Tahk S; Yang R; Mink S; Shultz D; Bellone CJ; Loo JA; Shuai K
Cell; 2007 Jun; 129(5):903-14. PubMed ID: 17540171
[TBL] [Abstract][Full Text] [Related]
9. Identification of the SUMO E3 ligase PIAS1 as a potential survival biomarker in breast cancer.
Chanda A; Chan A; Deng L; Kornaga EN; Enwere EK; Morris DG; Bonni S
PLoS One; 2017; 12(5):e0177639. PubMed ID: 28493978
[TBL] [Abstract][Full Text] [Related]
10. PIAS1 interacts with and represses SOX9 transactivation activity.
Oh HJ; Kido T; Lau YF
Mol Reprod Dev; 2007 Nov; 74(11):1446-55. PubMed ID: 17440973
[TBL] [Abstract][Full Text] [Related]
11. PIAS1 binds p300 and behaves as a coactivator or corepressor of the transcription factor c-Myb dependent on SUMO-status.
Ledsaak M; Bengtsen M; Molværsmyr AK; Fuglerud BM; Matre V; Eskeland R; Gabrielsen OS
Biochim Biophys Acta; 2016 May; 1859(5):705-18. PubMed ID: 27032383
[TBL] [Abstract][Full Text] [Related]
12. Functional interaction of AIRE with PIAS1 in transcriptional regulation.
Ilmarinen T; Kangas H; Kytömaa T; Eskelin P; Saharinen J; Seeler JS; Tanhuanpää K; Chan FY; Slattery RM; Alakurtti K; Palvimo JJ; Ulmanen I
Mol Immunol; 2008 Apr; 45(7):1847-62. PubMed ID: 18083234
[TBL] [Abstract][Full Text] [Related]
13. PIAS1 protects against myocardial ischemia-reperfusion injury by stimulating PPARγ SUMOylation.
Xie B; Liu X; Yang J; Cheng J; Gu J; Xue S
BMC Cell Biol; 2018 Nov; 19(1):24. PubMed ID: 30419807
[TBL] [Abstract][Full Text] [Related]
14. PIAS1 and TIF1γ collaborate to promote SnoN SUMOylation and suppression of epithelial-mesenchymal transition.
Chanda A; Ikeuchi Y; Karve K; Sarkar A; Chandhoke AS; Deng L; Bonni A; Bonni S
Cell Death Differ; 2021 Jan; 28(1):267-282. PubMed ID: 32770107
[TBL] [Abstract][Full Text] [Related]
15. Selective transcriptional regulation by Myc in cellular growth control and lymphomagenesis.
Sabò A; Kress TR; Pelizzola M; de Pretis S; Gorski MM; Tesi A; Morelli MJ; Bora P; Doni M; Verrecchia A; Tonelli C; Fagà G; Bianchi V; Ronchi A; Low D; Müller H; Guccione E; Campaner S; Amati B
Nature; 2014 Jul; 511(7510):488-492. PubMed ID: 25043028
[TBL] [Abstract][Full Text] [Related]
16. FoxO3 suppresses Myc-driven lymphomagenesis.
Vandenberg CJ; Motoyama N; Cory S
Cell Death Dis; 2016 Jan; 6(1):e2046. PubMed ID: 26764572
[TBL] [Abstract][Full Text] [Related]
17. Tumor Suppressor p14ARF Enhances IFN-γ-Activated Immune Response by Inhibiting PIAS1 via SUMOylation.
Alagu J; Itahana Y; Sim F; Chao SH; Bi X; Itahana K
J Immunol; 2018 Jul; 201(2):451-464. PubMed ID: 29848755
[TBL] [Abstract][Full Text] [Related]
18. Myc-induced SUMOylation is a therapeutic vulnerability for B-cell lymphoma.
Hoellein A; Fallahi M; Schoeffmann S; Steidle S; Schaub FX; Rudelius M; Laitinen I; Nilsson L; Goga A; Peschel C; Nilsson JA; Cleveland JL; Keller U
Blood; 2014 Sep; 124(13):2081-90. PubMed ID: 25143484
[TBL] [Abstract][Full Text] [Related]
19. SUMOylation by the E3 ligase TbSIZ1/PIAS1 positively regulates VSG expression in Trypanosoma brucei.
López-Farfán D; Bart JM; Rojas-Barros DI; Navarro M
PLoS Pathog; 2014 Dec; 10(12):e1004545. PubMed ID: 25474309
[TBL] [Abstract][Full Text] [Related]
20. Akt SUMOylation regulates cell proliferation and tumorigenesis.
Li R; Wei J; Jiang C; Liu D; Deng L; Zhang K; Wang P
Cancer Res; 2013 Sep; 73(18):5742-53. PubMed ID: 23884910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
